Paclitaxel by 96-hour continuous infusion in combination with cisplatin : A phase I trial in patients with advanced lung cancer
作者： M S Georgiadis , B S Schuler , J E Brown , L V Kieffer , S M Steinberg
DOI: 10.1200/JCO.1997.15.2.735
关键词:
摘要: PURPOSETo determine the maximum-tolerated dose (MTD) of paclitaxel administered by 96-hour continuous infusion in combination with cisplatin, to if addition granulocyte colony-stimulating factor (G-CSF) permits significant escalation, and assess toxicity preliminary activity this patients advanced lung cancer.PATIENTS AND METHODSFifty untreated cancer were enrolled: 42 had non-small-cell (NSCLC) eight extensive-stage small-cell (SCLC). Patients received doses 100 180 mg/m2/96 hours cisplatin 60 80 mg/m2 as a single 30-minute bolus injection at end infusion.RESULTSTwo six experienced dose-limiting neutropenia 140 mg/m2. With G-CSF support, one three both mucositis fatal neutropenic sepsis mg/...
sci-hub.se 参考文章(26)
Schilsky R, Reddick Rl, Reichert Cm, Von Hoff Dd, Muggia Fm, Rozencweig M, Young Rc, Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer treatment reports. ,vol. 63, pp. 1527- 1531 ,(1979)
E K Rowinsky, M R Gilbert, W P McGuire, D A Noe, L B Grochow, A A Forastiere, D S Ettinger, B G Lubejko, B Clark, S E Sartorius, Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study Journal of Clinical Oncology. ,vol. 9, pp. 1692- 1703 ,(1991) , 10.1200/JCO.1991.9.9.1692
C J Langer, J C Leighton, R L Comis, P J O'Dwyer, C A McAleer, C A Bonjo, P F Engstrom, S Litwin, R F Ozols, Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. Journal of Clinical Oncology. ,vol. 13, pp. 1860- 1870 ,(1995) , 10.1200/JCO.1995.13.8.1860
E A Eisenhauer, W W ten Bokkel Huinink, K D Swenerton, L Gianni, J Myles, M E van der Burg, I Kerr, J B Vermorken, K Buser, N Colombo, European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology. ,vol. 12, pp. 2654- 2666 ,(1994) , 10.1200/JCO.1994.12.12.2654
A D Seidman, D Hochhauser, M Gollub, B Edelman, T J Yao, C A Hudis, P Francis, D Fennelly, T A Gilewski, M E Moynahan, V Currie, J Baselga, W Tong, M O'Donaghue, R Salvaggio, L Auguste, D Spriggs, L Norton, Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Journal of Clinical Oncology. ,vol. 14, pp. 1877- 1884 ,(1996) , 10.1200/JCO.1996.14.6.1877
James D. Cotelingam, John D. Minna, Adi F. Gazdar, Adi F. Gazdar, Seth M. Steinberg, Daniel C. Ihde, Bimal C. Ghosh, Harvey I. Pass, Ruby Phelps, Bruce E. Johnson, James L. Mulshine, R. Ilona Linnoila, Herbert K. Oie, Gail L. Shaw, Thomas E. Walsh, John C. Nesbitt, Individualized Chemotherapy for Patients with Non-Small Cell Lung Cancer Determined by Prospective Identification of Neuroendocrine Markers and in Vitro Drug Sensitivity Testing Cancer Research. ,vol. 53, pp. 5181- 5187 ,(1993)
W H Wilson, B A Chabner, G Bryant, S Bates, A Fojo, J Regis, E S Jaffe, S M Steinberg, B R Goldspiel, B D Cheson, Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. Journal of Clinical Oncology. ,vol. 13, pp. 381- 386 ,(1995) , 10.1200/JCO.1995.13.2.381
J D Hainsworth, D S Thompson, F A Greco, Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 13, pp. 1609- 1614 ,(1995) , 10.1200/JCO.1995.13.7.1609
M L Slevin, P I Clark, S P Joel, S Malik, R J Osborne, W M Gregory, D G Lowe, R H Reznek, P F Wrigley, A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. Journal of Clinical Oncology. ,vol. 7, pp. 1333- 1340 ,(1989) , 10.1200/JCO.1989.7.9.1333
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25